Stockholders' Equity (Narrative) (Details) - USD ($)					1 Months Ended			9 Months Ended	12 Months Ended
	Dec. 08, 2021	Mar. 09, 2021	Feb. 11, 2021	Apr. 01, 2020	Oct. 18, 2021	Nov. 25, 2020	Oct. 28, 2019	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Feb. 11, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized	100,000,000								100,000,000	50,000,000
Common stock, shares issued									46,450,250	25,085,534
Common stock, shares outstanding									46,450,250	25,085,534
Preferred stock, shares authorized									10,000,000	10,000,000
Preferred stock, shares issued									0	0
Preferred stock, shares outstanding									0	0
Proceeds from issuance of common stock, net of issuance costs									$ 1,483,833	$ 15,821,922
Stock options, granted									415,000	1,525,000
Share-based compensation, tax benefit from compensation expense									$ 1,000,000.0
Employee service share-based compensation, non-vested awards, compensation cost not yet recognized, period for recognition									2 years 6 months
Share-based compensation arrangement by share-based payment award, options, vested in period, fair value									$ 622,757	$ 549,341
Preferred Stock, Par or Stated Value Per Share									$ 0.01	$ 0.01
Deemed dividend on beneficial conversion feature									$ 7,166,752
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee service share-based compensation, non-vested awards, compensation cost not yet recognized, period for recognition									1 year
Employee service share-based compensation, non-vested awards, compensation cost not yet recognized, total									$ 320,000
2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares authorized									2,710
Share-based compensation arrangement by share-based payment award, description									the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) 4% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Company’s Board of Directors.
Share-based compensation arrangement by share-based payment award, number of shares available for grant									465,586
Share-based compensation arrangement by share-based payment award, common stock percentage									4.00%
2020 Stock Options Plan [Member] | ExecutiveOfficers And Non-Employee Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares available for future issuance, shares								1,300,000
Stock issued during period, shares, new issues								1,300,000
Stock options, granted								1,300,000
2016 Stock Option Plan [Member] | Replacement Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value of options awarded										$ 1.68
Number of share options granted										134,371
Curetis GmbH [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Acquisition of shares				2,028,208
Common Stock [Member] | H.C. Wainwright & Co., LLC [Member] | 2020 ATM Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues									680,000	7,521,610
Proceeds from issuance of common stock, net of issuance costs									$ 1,480,000	$ 15,800,000
Gross proceeds from sale of common stock									1,550,000	16,700,000
Remaining availability under market offering									3,900,000
Common Stock [Member] | H.C. Wainwright & Co., LLC [Member] | 2020 ATM Offering [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares available for future issuance amount											$ 22,100,000
New Warrants [Member] | Holder pursuant to company issued to Holder securities [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of each warrant issue to purchase common stock		0.65
Class of warrant or right, exercise price of warrants or rights		$ 3.56
Issuance of common stock warrants to purchase		3,147,700
Warrants expiry period		5 years
Payment to purchase new warrants		$ 255,751
Warrants [Member] | Holder pursuant to company issued to Holder securities [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of warrant		9,650,000
Non-cash warrant inducement expense		$ 7,800,000
October 2019 Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues							2,590,170
Shares issued, price per share							$ 2.00
October 2019 Public Offering [Member] | Common Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of common stock, net of issuance costs									$ 10,000	$ 8,700,000
Warrants exercised									5,000	4,341,000
October 2019 Public Offering [Member] | Pre-funded Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues							2,109,830
Shares issued, price per share							$ 1.99
Gross proceeds from sale of common stock and warrants							$ 9,400,000
Net proceeds from sale of common stock and warrants							$ 8,300,000
2020 PIPE [Member] | Healthcare-focused U.S. Institutional Investor [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues						2,245,400
Proceeds from issuance of common stock, net of issuance costs						$ 9,300,000
Gross proceeds from sale of common stock						$ 10,000,000.0
Shares issued, price per share						$ 2.065
Class of warrant or right, exercise price of warrants or rights						$ 1.94
Warrants exercisable period						6 months
Warrants exercised		4,842,615				4,842,615
Issuance of common stock warrants to purchase						2,245,400
Warrants expiry period						5 years 6 months
Sale of stock, description of transaction						with each pre-funded warrant exercisable for one share of common stock
2020 PIPE [Member] | Healthcare-focused U.S. Institutional Investor [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues						2,245,400
2020 PIPE [Member] | Pre Funded Warrant [Member] | Healthcare-focused U.S. Institutional Investor [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues						2,597,215
Shares issued, price per share						$ 2.055
Warrants exercised						2,597,215
Issuance of common stock warrants to purchase						2,597,215				2,597,215
Sale of stock, description of transaction									each pre-funded warrant exercisable for one share of common stock
February 2021 Offering [Member] | Healthcare-focused Institutional Investor [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues			2,784,184
Proceeds from issuance of common stock, net of issuance costs			$ 23,500,000
Gross proceeds from sale of common stock			$ 25,000,000.0
Sale of stock, description of transaction			each pre-funded warrant exercisable for one share of common stock
February 2021 Offering [Member] | Investor [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued, price per share			$ 3.00
Class of warrant or right, exercise price of warrants or rights			$ 3.55
Warrants exercisable period			6 months
Warrants expiry period			5 years 6 months
February 2021 Offering [Member] | Pre Funded Warrant [Member] | Healthcare-focused Institutional Investor [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues			5,549,149						5,549,149
Warrants exercised			4,166,666
Sale of stock, description of transaction									each pre-funded warrant exercisable for one share of common stock.
February 2021 Offering [Member] | Pre Funded Warrant [Member] | Investor [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued, price per share			$ 2.99
Class of warrant or right, exercise price of warrants or rights			$ 0.01
October 2021 Offering [Member] | Healthcare-focused Institutional Investor [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues	150,000				150,000
Proceeds from issuance of common stock, net of issuance costs					$ 13,900,000
Gross proceeds from sale of common stock					$ 15,000,000.0
Class of warrant or right, exercise price of warrants or rights					$ 2.05
Warrants exercisable period					6 months
Warrants expiry period					5 years
Preferred Stock, Par or Stated Value Per Share					$ 100
Conversion preferred stock per share					$ 2.00
Convertible preferred stock	7,500,000				7,500,000				7,500,000
October 2021 Offering [Member] | Warrants [Member] | Healthcare-focused Institutional Investor [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues					7,500,000